Recent studies in CLL have shown that an inhibitory antibody targeting ROR1, cirmtuzumab, in combination with the BCL2 inhibitor venetoclax demonstrated synergy, indicating that the combined therapy has a greater clinical impact than either therapy alone6. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.